This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
SS-31 treatment in diabetic mice significantly reduced proteinuria, oxidative DNA damage, renal fibrosis markers, and apoptosis in kidney cells. It inhibited key oxidative stress pathways including NADPH oxidase activity and restored mitochondrial function in mouse mesangial cells exposed to high glucose.
Why it matters
This research highlights SS-31 as a promising mitochondria-targeted antioxidant peptide that can protect against diabetic kidney injury, a major complication of diabetes. Understanding its mechanism may guide development of new therapies to prevent or treat diabetic nephropathy.
How the study worked
The study used diabetic CD-1 mice subjected to uninephrectomy and streptozotocin to induce diabetic nephropathy, followed by daily intraperitoneal injections of SS-31 for 8 weeks. In vitro experiments were conducted on mouse mesangial cells exposed to high-glucose conditions to assess SS-31's effects on oxidative stress and apoptosis.
What this study cannot tell us
The study was conducted in a mouse model and cultured cells, so results may not fully translate to humans. The exact clinical efficacy and safety of SS-31 in diabetic patients remain to be established.
Read the original research
Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy.
American journal of physiology. Renal physiology, 310(6), F547-59
Citation
Hou, Yanjuan; Li, Shuangcheng; Wu, Ming; Wei, Jinying; Ren, Yunzhuo; Du, Chunyang; Wu, Haijiang; Han, Caili; Duan, Huijun; Shi, Yonghong. (2016). Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy.. American journal of physiology. Renal physiology, 310(6), F547-59. https://doi.org/10.1152/ajprenal.00574.2014